Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recruiting × empagliflozin × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cardiotoxicity 1

Interventions

Cisplatin 88 Carboplatin 85 pembrolizumab 81 Gemcitabine 70 Paclitaxel 67 Docetaxel 63 Capecitabine 49 Oxaliplatin 47 Fluorouracil 47 Radiotherapy 45 Specimen Handling 44 Magnetic Resonance Spectroscopy 42 Bevacizumab 42 Cyclophosphamide 38 Pemetrexed 36 Dexamethasone 36 Leucovorin 35 Drug Therapy 35 Doxorubicin 33 Irinotecan 32 Rituximab 27 Injections 26 Vincristine 25 Lenalidomide 25 Trastuzumab 24 Radiosurgery 22 Radiation 22 Etoposide 22 toripalimab 21 Prednisone 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05271162 2025-11-21

EMPACT

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 3 Recruiting

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡